Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Medtronic
Daiichi Sankyo
Julphar
Boehringer Ingelheim
Cantor Fitzgerald
Dow
Chubb

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TYKERB

« Back to Dashboard

Clinical Trials for Tykerb

Trial ID Title Status Sponsor Phase Summary
NCT00095563 Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers Completed National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
NCT00095667 Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent or metastatic prostate cancer.
NCT00095940 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed National Cancer Institute (NCI) Phase 1/Phase 2 This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
NCT00096447 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
NCT00098605 Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Completed National Cancer Institute (NCI) Phase 2 Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating brain metastases in patients with stage IV breast cancer and brain metastases.
NCT00101036 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT00103194 Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 This phase II trial studies how well lapatinib ditosylate works in treating patients with a rising prostate-specific antigen (PSA), a protein made by the prostate gland, indicating that prostate cancer has come back after previous treatment. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may delay or prevent the progression of prostate cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tykerb

Condition Name

Condition Name for Tykerb
Intervention Trials
Stage IV Breast Cancer 11
Breast Cancer 10
HER2-positive Breast Cancer 7
Stage IIIC Breast Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tykerb
Intervention Trials
Breast Neoplasms 34
Carcinoma 13
Breast Neoplasms, Male 7
Adenocarcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tykerb

Trials by Country

Trials by Country for Tykerb
Location Trials
United States 280
Germany 17
United Kingdom 11
Canada 11
Korea, Republic of 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tykerb
Location Trials
California 17
Texas 15
Pennsylvania 13
New York 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tykerb

Clinical Trial Phase

Clinical Trial Phase for Tykerb
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 31
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tykerb
Clinical Trial Phase Trials
Completed 30
Active, not recruiting 13
Terminated 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tykerb

Sponsor Name

Sponsor Name for Tykerb
Sponsor Trials
National Cancer Institute (NCI) 30
GlaxoSmithKline 19
Novartis 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tykerb
Sponsor Trials
Other 34
NIH 30
Industry 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Baxter
Boehringer Ingelheim
Queensland Health
Express Scripts
UBS
Colorcon
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.